Health ❯ Healthcare

Pharmaceuticals

Drug Development Drug Approval Clinical Trials Drug Safety Drug Pricing Weight Loss Cancer Treatment Drug Regulation Medications Weight Loss Drugs

7 ARTICLES

7h ago

AstraZeneca Stops Phase III Volrustomig Lung Cancer Trial

An IDMC concluded the drug combo was unlikely to meet survival endpoints in PD‑L1 negative patients, prompting the company to end the study while other volrustomig programs continue.

6 ARTICLES

9h ago

U.S. Prescription Drug Prices Post Largest Annual Drop Since 1963

3 ARTICLES

16h ago

Enhertu Improves Progression‑Free Survival in Phase 3 HER2‑Mutant Lung Cancer Trial

Stories older than 24h

5 ARTICLES

yesterday

UK Approves Lilly’s Oral GLP‑1 Pill Foundayo

9 ARTICLES

4d ago

Novo Nordisk Sues Lilly Over Weight‑Loss Ads as GLP‑1 Rivalry Intensifies

3 ARTICLES

5d ago

FDA Authorizes Intermountain to Give Investigational KRAS Drug to Pancreatic Cancer Patients

3 ARTICLES

5d ago

HSE Drugs Group Recommends Against Funding Skyclarys as Final Vote Looms

13 ARTICLES

6d ago

UK Regulator Approves Eli Lilly’s Foundayo Tablet for Weight Loss and Type 2 Diabetes

3 ARTICLES

6d ago

One-Time Triple Regimen Clears HIV in Infant Macaque Model

6 ARTICLES

last wk.

AbCellera’s Menopause Antibody Hits Phase 2 Goals

6 ARTICLES

last wk.

Lilly Posts Blowout Quarter as Global GLP‑1 Push Tests Price‑for‑Volume Strategy

4 ARTICLES

last wk.

Tenax Therapeutics Stock Collapses After Phase 3 Levosimendan Trial Misses Endpoints

3 ARTICLES

last wk.

Sionna Halts SION-719 After Mid-Stage Cystic Fibrosis Trial Misses Key Biomarker

46 ARTICLES

last wk.

FDA Approves Moderna’s mFlusiva for Adults 50 and Older

5 ARTICLES

last wk.

Bank of America Says It Pays Over $250 Million a Year for GLP‑1 Drugs

5 ARTICLES

last wk.

FDA Grants Accelerated Approval for RP1 (Tudriqev) With Nivolumab in Advanced Melanoma

13 ARTICLES

last wk.

Retailers Move to Fill $50 Medicare GLP‑1 Prescriptions

Pharmaceuticals

AstraZeneca Stops Phase III Volrustomig Lung Cancer Trial

U.S. Prescription Drug Prices Post Largest Annual Drop Since 1963

Enhertu Improves Progression‑Free Survival in Phase 3 HER2‑Mutant Lung Cancer Trial

UK Approves Lilly’s Oral GLP‑1 Pill Foundayo

Novo Nordisk Sues Lilly Over Weight‑Loss Ads as GLP‑1 Rivalry Intensifies

FDA Authorizes Intermountain to Give Investigational KRAS Drug to Pancreatic Cancer Patients

HSE Drugs Group Recommends Against Funding Skyclarys as Final Vote Looms

UK Regulator Approves Eli Lilly’s Foundayo Tablet for Weight Loss and Type 2 Diabetes

One-Time Triple Regimen Clears HIV in Infant Macaque Model

AbCellera’s Menopause Antibody Hits Phase 2 Goals

Never miss stories about

Pharmaceuticals

Lilly Posts Blowout Quarter as Global GLP‑1 Push Tests Price‑for‑Volume Strategy

Tenax Therapeutics Stock Collapses After Phase 3 Levosimendan Trial Misses Endpoints

Sionna Halts SION-719 After Mid-Stage Cystic Fibrosis Trial Misses Key Biomarker

FDA Approves Moderna’s mFlusiva for Adults 50 and Older

Bank of America Says It Pays Over $250 Million a Year for GLP‑1 Drugs

FDA Grants Accelerated Approval for RP1 (Tudriqev) With Nivolumab in Advanced Melanoma

Mounjaro Study Finds Lower Heart‑Attack Risk as UK Safety Reports Rise

Lilly Pulls Further Ahead in GLP-1 Race After Blowout Quarter

FDA Approves Orzeyful as First Orexin Agonist for Narcolepsy Type 1

Retailers Move to Fill $50 Medicare GLP‑1 Prescriptions

Never miss stories about

Pharmaceuticals